Let's get some plant food on emerging foliate

New Post Public Reply Private Reply Replies (0) Message Board
PoemStone energy_wave #38811
98
Let's get some plant food
on emerging foliate crops.


$BLONF $0.2437
OTC Website
low float 51,151,840 / 06/20/2019
Barchart hold
filings and news


nlogo.jpg
.....................................................


< Mission To accelerate the growth of all value plants safely,
economically and naturally using our patented advanced
carbon dioxide technologies



< Canadian Stock Symbol
$GROW.V
United States Stock Symbol
$BLONF
$Frankfurt Stock Symbol
4O21

< Cannabis growers
< Corporate Presentation
< Interview videos


1582748_1600x0.jpg

1582751_1600x0.jpg





$BLONF FaQ:
< >

< CO2 Foliar Spray Patent Progress

Our CO2 Foliar Spray pending method of use PCT patent will be supported by further patent filings and a second distinct patent. For the retail market, we have filed for a hand-held device patent.

< Explain your CO2 Capture and Use on Plants Patent License

We have a global exclusive royalty free license for the use two gas infusion patents (2001 and 2009) to capture and dissolve CO2 gas via microporous hollow fiber technology for all plant growth. We are entitled under this license to manufacture our own devices.

< We are allowed to patent arising IP. 2019 Commercial Revenue

Our first two long term Commercial Agreements are on a per square foot lease basis. We cover capital expenditures related to our technology and set-up. Ourcustomers pay to adapt their irrigation to the CO2 Foliar Spray. Our publicly stated lease revenue target by year-end 2019 is C$10 entering 2020. We will provide consolidated data at the end of each quarter on run rate lease revenue.

< Inventory of Components and Manufacturers

We have three contract manufacturers that can make our desired CO2 Foliar Spray systems. We have inventory capable of irrigating over 5M square feet. We have sufficient inventory carry out numerous (12) trials simultaneously.

< Monitoring CO2

UseOur commercial CO2 Foliar Spray systems have remote monitoring telemetry that can be controlled remotely. The telemetry will indicate if the technology is being used beyond a particular site license limit.

< CO2 Gas Suppliers

We have multiple relationships with major CO2 gas suppliers for growers. Our customers will be paying for their CO2 gas supplies.
< Is CO2 Foliar Spray Organic?

Yes, provided our customer uses food grade CO2 from industrial suppliers. Ontario’s Pro Organic states that if CO2 gas is extracted from coal, cement or lime facilities, its extracted use would not be considered organic. Other Provinces and States have their own definitions.

We are getting more requests from organic growers that are constrained on the use of chemicals such as pesticides as our CO2 Foliar Spray also has natural resistance features to pathogens such as E. coli.
nce features to pathogens such as E. coli.
Featured stocks: Coffee Shoppe
For conservative debate: "Keeping it Real"
Game Changing stock $SHMP

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Alaska's Insurance Maze: Coverage Over Cheap Policies

Updated Category News Views 171

Beyond Premiums: Assessing Real Coverage Needs The Alaskan wilderness isn't just home to stunning views; it's also a land where insurance needs to go beyond the average cookie-cutter policy. You'd think the cheapest option would suffice, but that's where residents might trip into financial quicksand. Devery Prince, a seasoned insurance principal, sheds light on why...

Continue Reading
CapCut's AI Tools Reshape Video Content Creation

Updated Category News Views 185

AI Revolution in Marketing Content: CapCut Takes Lead It's like the old guard of marketing has hitched a ride on a rocket. In 2026, CapCut has stomped into the limelight with Better Business Advice giving them a nod for their prowess in AI-driven content creation. This isn't some passing trend; it's a seismic shift in how businesses craft their messages. CapCut ain't just...

Continue Reading
ASTS Faces Crucial Deadline Amidst Legal Turmoil

Updated Category News Views 176

Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...

Continue Reading
What to Expect: Your First Therapy Session Insights

Updated Category News Views 201

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

Continue Reading
Spooky Dining at CARNE: A Halloween Hit in Oxnard

Updated Category News Views 221

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 98

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 79

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 145

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Likang's Bold Move: Cancer Immunotherapy at AD Summit

Updated Category News Views 159

Cancer Care Takes Center Stage Kicking off with a bang in Abu Dhabi, Likang Life Sciences has made a splash in the world of personalized cancer immunotherapy. The Abu Dhabi Future Health Summit 2026 served as the backdrop for this bold move, lighting up discussions with their AI-enabled innovations. Likang's showing at the Summit wasn't just another walk in the park—it...

Continue Reading
Taiwan Fuses Ancient TCM with Modern Bio Tech in 2026

Updated Category News Views 207

The Dynamic Fusion of Heritage and Innovation When you think about it, mixing centuries-old herbal wisdom with today's cutting-edge biotech might sound like a plot twist, but that's exactly what's cooking in Taiwan. Over at SupplySide Global 2026 in Las Vegas, Taiwan's got something more than just traditional medicine to flaunt; it's showcasing an impressive fusion of...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Opportunities in Oversold Tech Stocks Today

Updated Category News Views 121

Market Dynamics and Oversold Stocks Recently, we witnessed a notable sell-off in the stock market, which was fueled by rising concerns surrounding the AI industry. As a result, many stocks experienced a significant pullback. Interestingly, this downturn did not discriminate and impacted various equities, including those unrelated to the AI sector. It's essential to...

Continue Reading
Innovative Device Revolutionizes Leg Recovery Process

Updated Category News Views 109

A Breakthrough in Leg Recovery: The LEG LIFTER Recovering from an injury or surgery can be a challenging process, especially when it comes to managing mobility. An inventive entrepreneur has come up with a unique solution to assist those dealing with leg injuries. The designer, based in Marietta, has developed the LEG LIFTER, a tool aimed at facilitating the lifting and...

Continue Reading
Vizsla Silver's New Strategic Acquisition Enhances Panuco Project

Updated Category News Views 78

Vizsla Silver Expands its Footprint with Key Acquisition In an exciting development, Vizsla Silver Corp. (NYSE: VZLA) (TSX: VZLA) has entered into an agreement to acquire significant claims that will bolster its already promising Panuco project. Ten new claims totaling 2,378 hectares have been purchased from Minera Fresnillo S.A. de C.V., a Fresnillo plc subsidiary. This...

Continue Reading
C3.ai Investors Seek Justice Amid Recent Stock Concerns

Updated Category News Views 91

Understanding the Situation for C3.ai Investors C3.ai, Inc. (NYSE: AI) has recently made headlines, not for positive advancements, but due to significant concerns regarding its stock performance and allegations of misleading statements. Shareholders who purchased shares during a specific class period might have encountered substantial losses, prompting the need for...

Continue Reading
Class Action Alert for Investors of Regeneron Pharmaceuticals

Updated Category News Views 139

Investors of Regeneron Pharmaceuticals Urged to Act In the bustling world of biotechnology, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has captured significant attention. Recently, the exceptionally reputable Rosen Law Firm announced a class action lawsuit, bringing notice to shareholders who have purchased securities from November 2, 2023, to October 30, 2024. This...

Continue Reading